Form 4: Lexicon Pharmaceuticals Director Diane E. Sullivan Reports Stock Option and Restricted Stock Unit Grants

Director Diane E. Sullivan reports the acquisition of stock options and restricted stock units in Lexicon Pharmaceuticals.

Summary

• On May 13, 2024, Diane E. Sullivan, a director of Lexicon Pharmaceuticals, reported the acquisition of 44,906 stock options with an exercise price of $1.79.
• These options vest in three equal installments on the first three anniversaries of the grant date and expire on May 13, 2034.
• Sullivan also acquired 36,810 restricted stock units (RSUs), each representing a contingent right to receive one share of common stock.
• These RSUs vest 100% on the first anniversary of the grant date.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine disclosure of stock options and RSU grants to a director. It doesn't indicate any significant positive or negative development for the company.

Positives

• The grant of stock options and RSUs to a director aligns their interests with those of the shareholders.
• The vesting schedules encourage long-term commitment from the director.

Industry Context

The granting of stock options and restricted stock units is a common practice in the pharmaceutical industry to incentivize and retain key personnel.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation practices across the pharmaceutical industry.
• Companies like Amgen, Gilead, and Biogen also utilize similar equity-based compensation plans for their directors and executives.
• The vesting schedules (three years for options, one year for RSUs) are also typical within the industry.

Stakeholder Impact

• The grant of stock options and RSUs aligns the director's interests with those of the shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates